Vor Bio to Participate in Upcoming Investor Conferences
Vor Bio (Nasdaq: VOR) will participate in upcoming investor conferences, including the Stifel 2023 Healthcare Conference, the 6th Annual Evercore ISI HealthCONx Conference, and the Piper Sandler 35th Annual Healthcare Conference.
11/03/2023 - 08:00 AM
CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Stifel 2023 Healthcare Conference
A live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com .
6th Annual Evercore ISI HealthCONx Conference : Wednesday, November 29, 2023 at 3:00 pm ET
Piper Sandler 35th Annual Healthcare Conference
About Vor Bio www.vorbio.com .
Contact:
Media & Investorssspencer@vorbio.com
Which investor conferences will Vor Bio participate in?
Vor Bio will participate in the Stifel 2023 Healthcare Conference, the 6th Annual Evercore ISI HealthCONx Conference, and the Piper Sandler 35th Annual Healthcare Conference.
When is the fireside chat at the Stifel 2023 Healthcare Conference?
The fireside chat at the Stifel 2023 Healthcare Conference will be held on Tuesday, November 14, 2023 at 3:35 pm ET.
Where will the fireside chat at the Evercore ISI HealthCONx Conference take place?
The fireside chat at the Evercore ISI HealthCONx Conference will take place at the Kimpton EPIC Hotel in Miami, FL.
When is the fireside chat at the Piper Sandler 35th Annual Healthcare Conference?
The fireside chat at the Piper Sandler 35th Annual Healthcare Conference will be held on Thursday, November 30, 2023 at 2:00 pm ET.
Where can I access the webcast and archived replay of the fireside chat?
The webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com.
Vor Biopharma Inc
NASDAQ:VOR
VOR Rankings
#4827 Ranked by Stock Gains
VOR Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
About VOR
vor biopharma is pioneering engineered hematopoietic stem cells (ehscs) to dramatically change the treatment paradigm for hematological cancers. vor’s ehscs are designed to generate healthy, fully functional cells with specific advantageous modifications, for example to protect the blood and bone marrow from the toxic effects of antigen-targeted therapies, protecting healthy cells from depletion but leaving tumor cells vulnerable. vor’s platform could potentially be used to change the treatment paradigm of both hematopoietic stem cell transplants and antigen-targeted therapies such as antibody drug conjugates, bispecific antibodies and car-t cell treatments. a proof-of-concept study for vor’s lead program has been published in proceedings of the national academy of sciences. vor is based in cambridge, mass. and has a broad intellectual property base including in-licenses from columbia university, where foundational work was conducted by inventor and vor scientific board chair siddhar
